A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging

• Published in: Neurology Vol. 99; no. 7; p. e669
• Main Authors: Dumurgier, Julien, Sabia, Séverine, Zetterberg, Henrik, Teunissen, Charlotte E, Hanseeuw, Bernard, Orellana, Adelina, Schraen, Susanna, Gabelle, Audrey, Boada, Mercè, Lebouvier, Thibaud, Willemse, Eline A J, Cognat, Emmanuel, Ruiz, Agustin, Hourregue, Claire, Lilamand, Matthieu, Bouaziz-Amar, Elodie, Laplanche, Jean-Louis, Lehmann, Sylvain, Pasquier, Florence, Scheltens, Philip, Blennow, Kaj, Singh-Manoux, Archana, Paquet, Claire
• Format: Journal Article
• Language: English
• Published: United States 16.08.2022
• Subjects: Aged; Alzheimer Disease - diagnostic imaging; Amyloid beta-Peptides; Biomarkers - cerebrospinal fluid; Female; Humans; Male; Peptide Fragments; Positron-Emission Tomography; tau Proteins
• ISSN: 1526-632X; 0028-3878; 1526-632X
• DOI: 10.1212/WNL.0000000000200735

To elaborate a new algorithm to establish a standardized method to define cutoffs for CSF biomarkers of Alzheimer disease (AD) by validating the algorithm against CSF classification derived from PET imaging. Low and high levels of CSF phosphorylated tau were first identified to establish optimal cutoffs for CSF β-amyloid (Aβ) peptide biomarkers. These Aβ cutoffs were then used to determine cutoffs for CSF tau and phosphorylated tau markers. We compared this algorithm to a reference method, based on tau and amyloid PET imaging status (ADNI study), and then applied the algorithm to 10 large clinical cohorts of patients. A total of 6,922 patients with CSF biomarker data were included (mean [SD] age: 70.6 [8.5] years, 51.0% women). In the ADNI study population (n = 497), the agreement between classification based on our algorithm and the one based on amyloid/tau PET imaging was high, with Cohen's kappa coefficient between 0.87 and 0.99. Applying the algorithm to 10 large cohorts of patients (n = 6,425), the proportion of persons with AD ranged from 25.9% to 43.5%. The proposed novel, pragmatic method to determine CSF biomarker cutoffs for AD does not require assessment of other biomarkers or assumptions concerning the clinical diagnosis of patients. Use of this standardized algorithm is likely to reduce heterogeneity in AD classification.